2023, July 19 – Free CE Webinar | PetDx®

Events

Loading Events

« All Events

  • This event has passed.

2023, July 19 – Free CE Webinar

July 19 @ 4:00 pm - 5:00 pm PDT

FREE

Register for Webinar


Webinar

How veterinarians are using liquid biopsy for cancer detection in dogs: a look at clinical performance and real-world results

Once a test has been validated and is commercially available, it is important for the laboratory to periodically report utilization and performance metrics regarding the test. Blood-based liquid biopsy using next-generation sequencing became clinically available in May 2021. Since that time, the test has been ordered for thousands of patients, primarily as a screening tool for dogs at higher risk of cancer, and as an aid in diagnosis for dogs for which there is a clinical suspicion of cancer. This session will review data from a cohort of 1,500 consecutive liquid biopsy tests received for commercial testing at one clinical laboratory, and will include a discussion of ordering patterns, positivity rates, and patient outcome data, along with how this data can be used to discuss liquid biopsy testing with clients. A series of interesting case studies will be presented, exploring the use of this testing in a variety of clinical settings.

Race: 20-977084

This program has been approved for 1 hour of continuing education credit in jurisdictions that recognize RACE approval.

Additionally, PetDx is approved as a New York State sponsor of continuing education for veterinarians and veterinary technicians.

Speaker

Todd Cohen

DVM, DACVIM (SAIM)
PetDx Director of Clinical Support


Register for Webinar

Details

Date:
July 19
Time:
4:00 pm - 5:00 pm PDT
Cost:
FREE
Event Category:
Website:
https://petdx.events/23-07-19/free-ce-webinar

Venue

GoToWebinar

Organizer

PetDx
Phone:
(833)-464-7297
Email:
education@petdx.com
View Organizer Website

Join the Revolution in Early Cancer Detection for Dogs

If you are ready to add the OncoK9 multi-cancer early detection test to your veterinary practice, we would love to hear from you.

Top